mk 0591 has been researched along with Cancer of Prostate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chakraborty, D; Chitale, D; Ghosh, J; Sarveswaran, S; Sears, R | 1 |
| Ghosh, J; Myers, CE; Sarveswaran, S | 1 |
2 other study(ies) available for mk 0591 and Cancer of Prostate
| Article | Year |
|---|---|
Inhibition of 5-lipoxygenase selectively triggers disruption of c-Myc signaling in prostate cancer cells.
Topics: 5-Lipoxygenase-Activating Protein Inhibitors; Apoptosis; Arachidonate 5-Lipoxygenase; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Indoles; Lipoxygenase Inhibitors; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Quinolines; Signal Transduction; Transcription, Genetic | 2015 |
MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase.
Topics: Apoptosis; Cell Survival; Chromones; Drug Synergism; Enzyme Inhibitors; Humans; Indoles; Lipoxygenase Inhibitors; Male; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Quinolines | 2010 |